Form 4: Nuvalent CDO Sells Shares After Option Exercise

Nuvalent's Chief Development Officer, Darlene Noci, exercised stock options and subsequently sold a portion of her Class A Common Stock under a pre-arranged 10b5-1 trading plan.

Summary

• Darlene Noci, Chief Development Officer of Nuvalent, Inc. (NUVL), reported transactions on March 30, 2026.
• Noci acquired 5,500 shares of Class A Common Stock by exercising stock options at a price of $27.85 per share.
• Following the option exercise, Noci sold 2,532 shares of Class A Common Stock at a weighted average price of $97.43 per share, with prices ranging from $96.84 to $97.83.
• Additionally, Noci sold another 2,968 shares of Class A Common Stock at a weighted average price of $98.13 per share, with prices ranging from $97.84 to $98.63.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Noci on November 18, 2024.
• After these reported transactions, Noci directly beneficially owns 58,117 shares of Class A Common Stock.
• Noci also holds 97,829 derivative securities in the form of stock options, with an exercise price of $27.85 and an expiration date of January 6, 2033. These options vest over four years following January 6, 2023, in equal monthly installments, subject to continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine insider transaction under a pre-arranged plan, which typically has a neutral impact on market sentiment as it is often related to executive compensation and personal financial planning rather than a change in company fundamentals.

Positives

• The Chief Development Officer successfully monetized stock options, indicating personal financial gain from the company's stock performance.
• The transactions were conducted under a Rule 10b5-1 trading plan, suggesting a pre-planned sale not based on recent non-public information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived by the market as a lack of confidence, although this is mitigated by the pre-arranged nature of the plan.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction, as it is solely a report of insider transactions.

Industry Context

StockSavvy.ai notes that insider sales under Rule 10b5-1 plans are a common practice for executives to manage their personal finances, diversify their portfolios, and exercise vested compensation. These pre-arranged plans help mitigate concerns about insiders trading on material non-public information, as the decision to sell is made in advance. Such transactions are generally viewed as routine and typically do not signal a change in the company's fundamental outlook or operational performance within the biotechnology or pharmaceutical industry.

Stakeholder Impact

• Shareholders: The exercise of options and subsequent sale of shares by an executive is a routine event related to compensation. While it involves a slight increase in outstanding shares from the option exercise, the overall impact on existing shareholders is generally minimal, especially given the pre-planned nature of the sale.

Next Steps

• The remaining stock options will continue to vest in equal monthly installments, subject to Darlene Noci's continued service to Nuvalent, Inc.

Key Dates

Recommendation

The reported transactions are routine insider activity involving the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 trading plan. Such transactions are common for executive compensation and personal financial planning and do not typically indicate a change in the company's fundamental outlook or warrant a shift in investment strategy based solely on this filing.

Keywords

Nuvalent, NUVL, insider trading, Form 4, stock option, share sale, Darlene Noci, Chief Development Officer, 10b5-1 plan